Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine
Key facts
- Where
- Groningen, Hilversum, Nieuwegein és Utrecht, HollandiaSee the 4 sites
- Phase
- 4. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Hollandia
- Universitair Medisch Centrum GroningenGroningen, HollandiaNo longer taking part
- TergooiziekenhuizenHilversum, HollandiaNo longer taking part
- Sint Antonius Ziekenhuis StichtingNieuwegein, HollandiaNo longer taking part
- Universitair Medisch Centrum UtrechtUtrecht, HollandiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitair Medisch Centrum Groningen
- Trial code
- EU 2024-518047-37-01
- Record updated
- 2024. december 16.
- Original description
The aim of our study is two folded: first, we aim to improve cognition after ECT, improving its acceptability and tolerability and hence increase its application. If ECT would be used for the calculated 26% of patients who have chronic severe depression, morbidity and mortality of this disorder would decrease steeply. Second, we aim to develop a prediction method based on clinical and EEG characteristics, to accurately predict who will respond to ECT. If it is possible to accurately predict ECT response (and non-response), it could be prevented that patients with a low chance of recovery receives ECT without response but with the associated risks.Read full original descriptionShow less
PRECISER; Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine
The aim of our study is two folded: first, we aim to improve cognition after ECT, improving its acceptability and tolerability and hence increase its application. If ECT would be used for the calculated 26% of patients who have chronic severe depression, morbidity and mortality of this disorder would decrease steeply. Second, we aim to develop a prediction method based on clinical and EEG characteristics, to accurately predict who will respond to ECT. If it is possible to accurately predict ECT response (and non-response), it could be prevented that patients with a low chance of recovery receives ECT without response but with the associated risks.
Inclusion: Age over 18 years; Clinical indication for ECT (as indicated by the treating physician/psychiatrist); Uni- or bipolar depression (as assessed by the treating psychiatrist); Dutch as first language.
Exclusion: Currently using rivastigmine, galantamine, donezepil (all cholinesterase inhibitors for mild to moderate Alzheimer’s Disease); Suspicion of neurodegenerative disorders (as diagnosed earlier); Contraindications for ECT (recent myocardinfarct, recent cerebrovasculair accident, recent intracranial surgery, pheochromocytoma and instable angina pectoris); Contraindications for rivastigmine (bradycardia or atrioventricular (AV) conduction disorders (first degree AV-block excluded)); Patients who have had an allergic reaction to rivastigmine; Cognitive disorder not explained by the depressive episode; Pregnancy and/or lactation/breast feeding.